Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia

被引：0
|
作者：
Yvyin Zhang
Peihong Wang
Yang Wang
Yang Shen
机构：
[1] State Key Laboratory of Medical Genomics,Shanghai Institute of Hematology
[2] National Research Center for Translational Medicine (Shanghai),Department of Hematology
[3] Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,undefined
[4] Guangzhou First People’s Hospital,undefined
[5] School of Medicine,undefined
[6] South China University of Technology,undefined
来源：
Biomarker Research | / 11卷
关键词：
Sitravatinib; -ITD; AML; Gilteritinib; Drug resistance; -ITD-F691L; FL; FGF2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
    Zhang, Yvyin
    Wang, Peihong
    Wang, Yang
    Shen, Yang
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [2] Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
    Juanjuan Zhao
    Yongping Song
    Delong Liu
    Biomarker Research, 7
  • [3] Plm-102, a Next Generation FLT3 Inhibitor, Shows Potent Anti-Leukemic Activity on Resistance to Gilteritinib in FLT3 Mutated Acute Myeloid Leukemia
    Lee, Jae-Seon
    Park, Min Ji
    Sun, Ningning
    Park, Jin-Hee
    Oh, Su-jin
    Moon, Miran
    Kim, Myung Jin
    Jang, Soo Yeon
    Kim, Yong-Chul
    BLOOD, 2023, 142
  • [4] AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
    Li, Cong
    Liu, Liqin
    Liang, Lingming
    Xia, Zhen
    Li, Zhihong
    Wang, Xianghong
    McGee, Lawrence R.
    Newhall, Katie
    Sinclair, Angus
    Kamb, Alexander
    Wickramasinghe, Dineli
    Dai, Kang
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 375 - 383
  • [5] PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia
    Nam, Ky-Youb
    Im, Jeejin
    Han, June H-J H-J
    Kim, Kyu-Tae
    Yoon, Jeong-Hyeok
    Cho, Hanna
    Choi, Seung-Hye
    Young, David
    Bao Nguyen
    Zhu, Ruiqi
    Li, Li
    Small, Donald
    Sim, Taebo
    BLOOD, 2020, 136
  • [6] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Masamichi Mori
    Naoki Kaneko
    Yoko Ueno
    Masaki Yamada
    Ruriko Tanaka
    Rika Saito
    Itsuro Shimada
    Kenichi Mori
    Sadao Kuromitsu
    Investigational New Drugs, 2017, 35 : 556 - 565
  • [7] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Mori, Masamichi
    Kaneko, Naoki
    Ueno, Yoko
    Yamada, Masaki
    Tanaka, Ruriko
    Saito, Rika
    Shimada, Itsuro
    Mori, Kenichi
    Kuromitsu, Sadao
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565
  • [8] Differential flt3 mutational status in acute myeloid leukemia predicts sensitivity to flt3 inhibitor gilteritinib in vitro and in vivo
    John, Bincy
    Sundaramoorthy, Pasupathi
    Rainbolt, Elizabeth
    Wong, Andrew
    Ward, Zachary
    Avery, Justin
    Todd, Savannah
    Kidder, Shasta
    Gietl, Diana
    Hall, Chassidy
    Harris, David
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia (vol 7, 19, 2019)
    Zhao, Juanjuan
    Song, Yongping
    Liu, Delong
    BIOMARKER RESEARCH, 2019, 7 (01)
  • [10] G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia
    Lee, Hee Kyu
    Kim, Hong Woo
    Lee, In Yong
    Lee, Jungmi
    Lee, Jaekyoo
    Jung, Dong Sik
    Lee, Sang Yeop
    Park, Sung Ho
    Hwang, Haejun
    Choi, Jang-Sik
    Kim, Jung-Ho
    Kim, Se Won
    Kim, Jung Keun
    Cools, Jan
    Koh, Jong Sung
    Song, Ho-Juhn
    BLOOD, 2014, 123 (14) : 2209 - 2219
12345